Scholar Rock Holding Corp (SRRK) 今日盘前股价大涨10.25%，引发市场关注。
消息面上，公司公布了第二季度财报，每股净亏损为0.84美元，较去年同期的0.98美元有所收窄。同时，公司披露其脊髓性肌萎缩症(SMA)药物apitegromab的申请正在接受FDA审查，且拥有两家灌装和包装工厂，为审批提供了两条独立路径，预计最迟将于9月30日获得审批决定。公司表示已准备好一旦获批即在美国上市该药物，且商业化供应充足。
此外，截至2026年6月30日，公司持有现金、现金等价物及有价证券共计4.921亿美元，为后续运营及商业化提供了坚实的资金保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.